|
Reasons for the recalls have ranged from contamination with metal shards and glass particles, to nauseating odors and inaccurate levels of active drug ingredients. Weldon said in an interview that J&J has eliminated some low-volume products made by its McNeil Consumer Healthcare unit and should have most of the others back by the middle of the year, with the rest returning by year's end. Analyst Steve Brozak of WBB Securities called the results lackluster. Like Gordon, he's concerned about profit margins declining due to multiple factors, including the costs of factory upgrades and litigation related to product recalls and increasing pricing pressures from government health programs. Excluding one-time items, J&J's operating margin fell 2 full percentage points for the year, to 24.9 percent, and dropped to 20.3 percent in the fourth quarter. Chief Financial Officer Dominic Caruso said he expects that will almost bounce back in 2012, when he expects earnings of $5.05 to $5.15 per share, excluding special items, and revenue of about $68 billion. Analysts expected earnings of $5.20 per share and revenue of $68.45 billion, according to FactSet. J&J said analysts likely had not updated their forecast to account for the recent surge of the dollar against the euro, which the company said will cut earnings per share by about 13 cents. For the full year, J&J reported net income of $9.67 billion, or $3.49 per share, down from $13.33 billion, or $4.78 per share, in 2010. Revenue rose 5.6 percent to $65.03 billion, from $61.59 billion in 2010. Shares of the company closed unchanged at $65.
[Associated
Press;
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor